Tags

Type your tag names separated by a space and hit enter

Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration.
Am J Ophthalmol. 2006 Jul; 142(1):10-16.AJ

Abstract

PURPOSE

To examine the efficacy of photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration (AMD).

DESIGN

Retrospective, interventional case series.

METHODS

Sixty eyes of 56 patients with neovascular AMD were treated with PDT with verteporfin followed by an intravitreal injection of 4 mg triamcinolone acetonide. The main outcome measures were visual acuity (VA), retreatment frequency with PDT (and triamcinolone), and frequency of side effects.

RESULTS

Mean follow-up was 15.9 months (range 12 to 30 months, median 15 months). Twenty-three (38.3%) of 60 eyes had a stable result at 12 months' follow-up (that is, loss/gain <three lines) and 34 (56.7%) of 60 had a loss of 3 lines or more. Three patients (5%) had an improvement of 3 lines or more. Lesion type, patient age, and lesion size had no influence on the outcome, but baseline VA had a statistically significant effect (P = .006). The median number of PDT-intravitreal triamcinolone acetonide treatments was one. One-third (20 of 60) of all eyes had an increase in intraocular pressure (IOP) that required therapy. There were no cases of endophthalmitis, but 13 patients (21.6%) developed severe cataract that required surgery.

CONCLUSIONS

The combination of PDT and intravitreal triamcinolone acetonide requires careful consideration as a treatment option for neovascular AMD. In our case series, this treatment combination did not prevent a considerable decrease in VA. The main benefit of this combination treatment was a low number of verteporfin treatments. Baseline VA was the main predictor of the final outcome.

Authors+Show Affiliations

Department of Ophthalmology, Sanatorium Hera, Vienna, Austria. erdem.ergun@chello.atNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16815246

Citation

Ergun, Erdem, et al. "Photodynamic Therapy With Verteporfin and Intravitreal Triamcinolone Acetonide in the Treatment of Neovascular Age-related Macular Degeneration." American Journal of Ophthalmology, vol. 142, no. 1, 2006, pp. 10-16.
Ergun E, Maár N, Ansari-Shahrezaei S, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol. 2006;142(1):10-16.
Ergun, E., Maár, N., Ansari-Shahrezaei, S., Wimpissinger, B., Krepler, K., Wedrich, A., & Stur, M. (2006). Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. American Journal of Ophthalmology, 142(1), 10-16.
Ergun E, et al. Photodynamic Therapy With Verteporfin and Intravitreal Triamcinolone Acetonide in the Treatment of Neovascular Age-related Macular Degeneration. Am J Ophthalmol. 2006;142(1):10-16. PubMed PMID: 16815246.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. AU - Ergun,Erdem, AU - Maár,Noémi, AU - Ansari-Shahrezaei,Siamak, AU - Wimpissinger,Barbara, AU - Krepler,Katharina, AU - Wedrich,Andreas, AU - Stur,Michael, PY - 2005/11/06/received PY - 2006/02/16/revised PY - 2006/02/21/accepted PY - 2006/7/4/pubmed PY - 2006/7/28/medline PY - 2006/7/4/entrez SP - 10 EP - 16 JF - American journal of ophthalmology JO - Am. J. Ophthalmol. VL - 142 IS - 1 N2 - PURPOSE: To examine the efficacy of photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration (AMD). DESIGN: Retrospective, interventional case series. METHODS: Sixty eyes of 56 patients with neovascular AMD were treated with PDT with verteporfin followed by an intravitreal injection of 4 mg triamcinolone acetonide. The main outcome measures were visual acuity (VA), retreatment frequency with PDT (and triamcinolone), and frequency of side effects. RESULTS: Mean follow-up was 15.9 months (range 12 to 30 months, median 15 months). Twenty-three (38.3%) of 60 eyes had a stable result at 12 months' follow-up (that is, loss/gain <three lines) and 34 (56.7%) of 60 had a loss of 3 lines or more. Three patients (5%) had an improvement of 3 lines or more. Lesion type, patient age, and lesion size had no influence on the outcome, but baseline VA had a statistically significant effect (P = .006). The median number of PDT-intravitreal triamcinolone acetonide treatments was one. One-third (20 of 60) of all eyes had an increase in intraocular pressure (IOP) that required therapy. There were no cases of endophthalmitis, but 13 patients (21.6%) developed severe cataract that required surgery. CONCLUSIONS: The combination of PDT and intravitreal triamcinolone acetonide requires careful consideration as a treatment option for neovascular AMD. In our case series, this treatment combination did not prevent a considerable decrease in VA. The main benefit of this combination treatment was a low number of verteporfin treatments. Baseline VA was the main predictor of the final outcome. SN - 0002-9394 UR - https://www.unboundmedicine.com/medline/citation/16815246/Photodynamic_therapy_with_verteporfin_and_intravitreal_triamcinolone_acetonide_in_the_treatment_of_neovascular_age_related_macular_degeneration_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9394(06)00343-6 DB - PRIME DP - Unbound Medicine ER -